Progentos Therapeutics
Watertown, US · Founded 2023 · Delaware corporation · 6 known investors
Find your way into Progentos Therapeutics
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
Founders & leadership
DH
CL
Christopher LooseNamed on SEC filing
SM
Sanjay MagaviNamed on SEC filing
MT
Board
AR
DJ
CB
Investors · 6
Reported raises · per SEC filings
Form D private placements$68.6M disclosed across 1 round · 2024
▶$68.6MraisedMay 2024 · 39 investors · OtherRule 506(b)
▶$68.6MraisedMay 2024 · 39 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Aleks Radovic-MorenoDirector
- Dmitrij HristodorovDirector
- Dan JanneyDirector
- Christopher LooseExecutive Officer, Director
- Cassidy BlundellDirector
- Sanjay MagaviExecutive Officer
- Marc-Olivier TurgeonDirector
- Offering amount
- $68.6M
- Amount sold
- $68.6M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Regeneron NASDAQ: REGN www.regeneron.com4 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Precigen4 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
PepGen4 shared keywordsPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Forbion Capital3 shared keywordsA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
Companies competing with Progentos Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Progentos Therapeutics do?
- Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
- Who are Progentos Therapeutics's investors?
- Progentos Therapeutics's investors include Alta Partners, Longwood Fund, Mission Biocapital, Service Provider Capital, Dolby Family Ventures, Forbion.
- How much funding has Progentos Therapeutics raised?
- Progentos Therapeutics has disclosed $68.6M raised across 1 round.
- Where is Progentos Therapeutics headquartered?
- Progentos Therapeutics is headquartered in Watertown, US.